Evidence map›Paper›PMID 42495656›Full record

ArticleLiver cancer2026

Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study.

Masayuki Ueno, Yung-Yeh Su, Atsushi Takai, Yi-Hsiang Huang, Hiroki Morimura, Norihiro Nishijima, Shi-Ming Lin, Ching-Wei Chang, Satoru Iwamoto, Shu Nagatomo and 24 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Masayuki UenoDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yung-Yeh SuNational Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
Atsushi TakaiDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yi-Hsiang HuangDepartment of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.
Hiroki MorimuraDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Norihiro NishijimaDepartment of Gastroenterology and Hepatology, Meiwa Hospital, Nishinomiya, Japan.
Shi-Ming LinDepartment of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.
Ching-Wei ChangDivision of Gastroenterology and Hepatology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan.
Satoru IwamotoDepartment of Gastroenterology, Kyoto Medical Center, Kyoto, Japan.
Shu NagatomoDepartment of Gastroenterology and Hepatology, Tenri Hospital, Tenri, Japan.
Hsueh-Chou LaiDepartment of Internal Medicine, Taichung Municipal Geriatric Rehabilitation General Hospital Taichung, Taichung, Taiwan.
Takeshi MitaniDepartment of Gastroenterology and Hepatology, Kurashiki Central Hospital, Kurashiki, Japan.
Atsuyuki IkedaDepartment of Gastroenterology and Hepatology, Kyoto Katsura Hospital, Kyoto, Japan.
Yoshito UenoyamaDepartment of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.
Makoto UmedaDepartment of Gastroenterology and Hepatology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.
San-Chi ChenDepartment of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
Chien-Huai ChuangDepartment of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
Shiue-Wei LaiDivision of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.
Teng-Yu LeeDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
Shigeharu NakanoDepartment of Gastroenterology and Hepatology, Medical Research Institute Kitano Hospital PIIF Tazuke Kofukai, Osaka, Japan.
Chia-Yen DaiDepartment of Internal Medicine and Department of Occupational and Environmental Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Tomoyuki GotoDepartment of Medical Oncology, Shiga General Hospital, Moriyama, Japan.
Tung-Hung SuDepartment of Medical Research, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan.
Ching Sheng HsuDivision of Gastroenterology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan.
Ching-Chu LoDivision of Gastroenterology, Department of Internal Medicine, St. Martin De Porres Hospital, Chiayi, Taiwan.
Haruhiko TakedaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yukio OsakiDepartment of Gastroenterology and Hepatology, Meiwa Hospital, Nishinomiya, Japan.
Etsuro HatanoDivision of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Pei-Chang LeeDepartment of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.
Po-Ting LinDepartment of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.
Hung-Wei WangCenter for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
Wei-Fan HsuCenter for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
Tsung-Hao LiuDepartment of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Hiroshi SenoDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Atezolizumab plus bevacizumab (Atezo+Bev) is the most widely used first-line treatment for unresectable hepatocellular carcinoma (HCC), while lenvatinib remains a standard alternative. Previous studies suggest limited efficacy of Atezo+Bev in patients with HCC exhibiting a CRAFITY score of 2 (CRP ≥1 mg/dL and AFP ≥100 ng/mL). We conducted an international collaborative study to compare the efficacy of Atezo+Bev and lenvatinib stratified by the baseline CRAFITY score. Methods: We retrospectively analyzed 994 patients who initiated Atezo+Bev or lenvatinib as first-line therapy for unresectable HCC between September 2017 and March 2024 across 11 hospitals in Japan and 13 hospitals in Taiwan. Patients were categorized by baseline CRAFITY score, and progression-free survival (PFS) and overall survival (OS) were compared between treatment groups. Results: The median age of the patients was 71 years, and 770 (77.5%) were male. The baseline CRAFITY score was 0 in 375 patients (37.7%), 1 in 402 patients (40.4%), and 2 in 217 patients (21.8%). In patients with a CRAFITY-0 score, median PFS (10.8 vs. 9.4 months; Conclusion: Lenvatinib was associated with significantly longer PFS than Atezo+Bev in patients with a baseline CRAFITY score of 2. The CRAFITY score may be useful for identifying patients in whom lenvatinib could be considered as a first-line option, and prospective validation is warranted.

Indexed as

Alpha-fetoproteinBiomarkerC-reactive proteinImmune checkpoint inhibitorLiver cancer

Identifiers

PMID42495656
PMCPMC13395466

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.